Trial
NCT05171062
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
Faron Pharmaceuticals Ltd
Condition
Non-small Cell Lung Cancer
Intervention
bexmarilimab (FP-1305)
Why stopped
No participants were enrolled, the study was inactivated with the IRB on May 15, 2023. The sponsor notified the PI that a Phase II trial had been allowed to proceed by the FDA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-20